The disclosure relates to an amylin polypeptide conjugate comprising a polypeptide component linked to a duration enhancing moiety. The duration enhancing moiety is linear polyethylene glycol. The disclosure also relates to the use of such a conjugate for the treatment of eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyperlipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis, osteoarthritis, or short bowel syndrome. The polypeptide has the following sequence: Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Xaa-Ser-Ser-Xaa-Asn-Phe-Xaa- Xaa-Xaa-Xaa-Xaa-Lys-Thr-Xaa-Val-Gly-Lys-Lys-Thr-Tyr-X wherein X and the various Xaa groups are defined in the specification
